SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rauch F, Glorieux FH 2004 Osteogenesis imperfecta. Lancet 363: 13771385.
  • 2
    Horewitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK 2001 Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97: 12271231.
  • 3
    Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L 2003 Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18: 126130.
  • 4
    Brumsen C, Hamdy NAT, Papapoulos SE 1997 Long-term effects of bisphosphonates on the growing skeleton: Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76: 266283.
  • 5
    Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G 1997 Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131: 622625.
  • 6
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947952.
  • 7
    Åström E, Söderhäll S 1998 Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Pediatr 87: 6468.
  • 8
    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 18461850.
  • 9
    Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J 2001 Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14: 529533.
  • 10
    Lee YS, Low SL, Lim LA, Loke KY 2001 Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 160: 641644.
  • 11
    Falk MJ, Heeger S, Lynch KA, De Caro KR, Bohach D, Gibson KS, Warman ML 2003 Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111: 573578.
  • 12
    Rauch F, Plotkin H, Zeitlin L, Glorieux FH 2003 Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res 18: 610614.
  • 13
    Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout AB, Schweitzer D, Uiterwaal C 2004 Skeletal effects and functional outcomes with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet 363: 14271431.
  • 14
    Fleisch H 2000 Bisphosphonates: Mechanism of action. Endocr Rev 19: 80100.
  • 15
    McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA 1987 Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8 (Suppl 1): S35S41.
  • 16
    Delmas PD, Chapuy MC, Edouard C, Meunier PJ 1987 Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 83: 276282.
  • 17
    Atkins RM, Yates AJ, Gray RE, Urwin GH, Hamdy NA, Beneton MN, Rosini S, Kanis JA 1987 Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res 2: 273279.
  • 18
    Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V 2002 Short-term intravenous therapy with neridronate in Paget's disease. Clin Exp Rheumatol 220: 5558.
  • 19
    Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, LoCascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41: 326331.
  • 20
    Adami S, Zamberlan N 1996 Adverse effects of bisphosphonates: A comparative review. Drug Saf 14: 158170.
  • 21
    Baron R, Gertner JM, Lang R, Vignery A 1983 Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 17: 204207.
  • 22
    Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S 2004 Bone turnover markers in patients with osteogenesis imperfecta. Bone 34: 10131016.
  • 23
    Rauch F, Travers R, Parfitt AM, Glorieux FH 2000 Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26: 581589.
  • 24
    Marini JC 2003 Do bisphosphonates make children's bones better or brittle? N Engl J Med 349: 423426.
  • 25
    Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF 1993 Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342: 14591460.
  • 26
    Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 394: 457463.